10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

COG3 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP11460b

Specification

COG3 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q96JB2

COG3 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 83548

Other Names
Conserved oligomeric Golgi complex subunit 3, COG complex subunit 3, Component of oligomeric Golgi complex 3, Vesicle-docking protein SEC34 homolog, p94, COG3, SEC34

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

COG3 Antibody (C-term) Blocking peptide - Protein Information

Name COG3

Synonyms SEC34

Function
Involved in ER-Golgi transport.

Cellular Location
Golgi apparatus, Golgi stack membrane; Peripheral membrane protein. Note=Associated with the peripheral membrane of cis/medial cisternae

Tissue Location
Widely expressed with highest levels in pancreas and testis and lowest levels in lung.

COG3 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

COG3 Antibody (C-term) Blocking peptide - Images

COG3 Antibody (C-term) Blocking peptide - Background

The protein encoded by this gene has similarity to a yeastprotein. It seems to be part of a peripheral membrane proteincomplex localized on cis/medial Golgi cisternae where it mayparticipate in tethering intra-Golgi transport vesicles. [providedby RefSeq].

COG3 Antibody (C-term) Blocking peptide - References

Laufman, O., et al. EMBO J. 28(14):2006-2017(2009)Shestakova, A., et al. Traffic 7(2):191-204(2006)Loh, E., et al. J. Biol. Chem. 279(23):24640-24648(2004)Dunham, A., et al. Nature 428(6982):522-528(2004)Gevaert, K., et al. Nat. Biotechnol. 21(5):566-569(2003)